These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24664166)

  • 1. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
    Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
    JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
    Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
    Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
    Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
    Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
    Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
    Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
    J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA; Puccio LM; Brydon EW
    J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis.
    Warnke C; Adams O; Kieseier B
    JAMA Neurol; 2014 Sep; 71(9):1192. PubMed ID: 25200545
    [No Abstract]   [Full Text] [Related]  

  • 13. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply.
    Frohman EM; Douek D; Major EO
    JAMA Neurol; 2014 Sep; 71(9):1192-3. PubMed ID: 25200546
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
    Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
    Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
    Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M
    Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
    Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
    J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.